{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:30:05Z","timestamp":1791379805134,"version":"4.3.3"},"reference-count":8,"publisher":"MedWorks Media","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Early-onset schizophrenia is notorious for poor prognostication and treatment-refractoriness. Clozapine remains a viable option, albeit off-label, but is clearly underutilized in this population. Use is typically fraught with panoply of drastic side effects. Here, authors report on an adolescent case with schizophrenia that responded ultimately to clozapine. Add-on viloxazine was advantageous spanning different symptom domains, mitigating metabolic parameters and addressing clozapine-sialorrhea. This might open new venues for such complicated, yet commonplace, clinical scenarios.<\/jats:p>","DOI":"10.64719\/pb.4427","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:39:16Z","timestamp":1761046756000},"page":"57-60","source":"Crossref","is-referenced-by-count":2,"title":["Successful Add-on Viloxazine to Clozapine-Responsive Schizophrenia Mitigated Cognitive, Negative and Metabolic Domains"],"prefix":"10.64719","volume":"52","author":[{"given":"Ahmed","family":"Naguy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reda","family":"Rushdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saxby","family":"Pridmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anubhuti","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bibi","family":"Alamiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Kasoff L, Ahn K, Gochman P et al. Strong Treatment Response and High Maintenance Rates of Clozapine in Childhood\u2014Onset Schizophrenia. Journal of Child and Adolescent Psychopharmacology. 2016;26(5):428\u2013435.","DOI":"10.1089\/cap.2015.0103"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Naguy A, Solanki APS, Alamiri B. Newly FDA-approved psychotropic agents- a recap. Asian Journal of Psychiatry. 2021;64:102786.","DOI":"10.1016\/j.ajp.2021.102786"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Naguy A, Alamiri B, Khraibut B. Weight Loss During Atomoxetine Add-on to Clozapine-Responsive Schizophrenia. American Journal of Therapeutics. 2018;25(6):e774\u2013e775.","DOI":"10.1097\/MJT.0000000000000785"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Nakanishi S, Kunugi H, Takahashi T. Efficacy of milnacipran for depressive symptoms in schizophrenia spectrum disorders. Psychiatry and Clinical Neuroscience. 2004;58:226\u2013227.","DOI":"10.1111\/j.1440-1819.2003.01222.x"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Yamamoto K, Hornykiewicz O. Proposal for noradrenaline hypothesis of schizophrenia. Progress in Neuropsychopharmacology and Biological Psychiatry. 2004;28:913\u2013922.","DOI":"10.1016\/j.pnpbp.2004.05.033"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Poyurovsky M, Fuchs C, Pashinian A et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacology (Berl). 2007;192(3):441\u2013448.","DOI":"10.1007\/s00213-007-0731-1"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Lu ML, Lane HY, Lin SK et al. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. Journal of Clinical Psychiatry. 2004;65(6):766\u2013771.","DOI":"10.4088\/JCP.v65n0607"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Stern RG, Bellucci D, Cursi-Vogel N et al. Clozapine-induced sialorrhea alleviated by bupropion- a case report. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(8):1578\u20131580.","DOI":"10.1016\/j.pnpbp.2009.09.014"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:30:12Z","timestamp":1791315012000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/successful-add-on-viloxazine-to-clozapine-responsive-schizophrenia-mitigated-cognitive-negative-and-metabolic-domains\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":8,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4427","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}